# Debate prop_0635__qwen3.8-max__claude-opus-5-5-high__s1__tpl_placement_active_20260813a

- topic_id: prop_0635
- proposition: AI model providers should face product-liability-style responsibility for foreseeable harms caused by deployed model behavior when reasonable safeguards were not implemented.
- model_pro: qwen3.8-max
- model_con: claude-opus-5-5-high
- side_swap: True

## Turn 1: PRO Opening

- model: qwen3.8-max
- raw_words: 296
- clipped_words: 296
- claim_ids: [P1.1], [P1.2], [P1.3], [P1.4], [P1.5]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P1.1] The core of this debate is who should pay when a company releases a powerful AI system without taking precautions that were cheap and obvious. The answer should be the company, not the injured public.
[P1.2] AI models are not magic; they are products. They are designed, trained, evaluated, priced, and shipped by firms that control the data, architecture, testing cloud, and release decisions. When a model is deployed into medicine, employment, finance, driving, or education, some harms are highly foreseeable: dangerous instructions, discriminatory decisions, false medical guidance, manipulation of vulnerable users. Product-liability-style responsibility simply says that if a provider knew or should have known about those risks and failed to implement reasonable safeguards, it must answer for resulting harm.
[P1.3] This is the standard we already apply to other complex technologies. A carmaker cannot sell a vehicle with brakes that predictably fail and argue that drivers should have noticed. A drugmaker cannot ignore known side effects and shift the cost to patients. AI providers have even greater informational advantage: model behavior can be opaque, risks can emerge only at scale, and ordinary users or downstream deployers cannot audit the system before harm occurs.
[P1.4] Reasonable safeguards are not speculative. They include red-teaming, capability evaluations, refusal rules for dangerous requests, human review in high-stakes settings, usage restrictions, monitoring for abuse, and transparent warnings. The proposition does not demand perfection or make providers insurers of every misuse. It ties liability to what was foreseeable and to precautions that were practicable.
[P1.5] That rule creates the right incentives. Today providers can capture benefits while socializing harms. Liability forces them to price safety into deployment, funds better safeguards, and gives victims a path to redress. If AI is mature enough to sell into high-risk markets, it is mature enough to carry ordinary responsibilities.

## Turn 2: CON Opening

- model: claude-opus-5-5-high
- raw_words: 356
- clipped_words: 340
- claim_ids: [C1.1], [C1.2], [C1.3], [C1.4], [C1.5], [C1.6], [C1.7], [C1.8], [C1.9], [C1.10]
- cited_claim_ids: [P1.2]
- missing_claim_id_refs: (none)

[C1.1] The proposition sounds modest because it borrows the vocabulary of brakes and pills. But a general-purpose model is not a brake. The case against this motion is that it puts liability on the wrong party, through the wrong instrument, at the wrong time.
[C1.2] First, the wrong party. PRO lists the danger zones [P1.2]: medicine, employment, finance, driving. Notice who chooses those settings. It is usually not the model provider.
[C1.3] It is the hospital that wires a chatbot into triage, the bank that automates loan decisions, the startup that skips human review. A brake has one job, so its maker knows how it will be used. A model can write poetry, debug code, or draft a diagnosis, and the deployer decides which. Product liability works when the manufacturer controls the use case.
[C1.4] Here the deployer controls it, so responsibility should follow the deployer, who already faces negligence law, consumer protection, and sector regulators.
[C1.5] Second, the wrong instrument. "Foreseeable harm" from a system that can say anything means almost every harm is foreseeable to a plaintiff's lawyer after the fact. "Reasonable safeguards" has no settled meaning yet. That means juries, case by case and in hindsight, would set AI safety standards across dozens of courts.
[C1.6] When an incident happens, every missing filter will look obvious. The result is not careful engineering but defensive engineering: refusing medical questions, legal questions, anything mildly risky. Users lose useful help, and they are not made meaningfully safer.
[C1.7] Third, the wrong time, and the wrong winners. The largest labs can absorb litigation, buy insurance, and staff compliance teams. Open-source developers, universities, and small competitors cannot. A developer who releases open model weights cannot monitor downstream use, yet would remain exposed for whatever someone builds later.
[C1.8] Liability here does not discipline the powerful. It shields them from competition.
[C1.9] None of this leaves victims stranded. Deployers can be held to duties tailored to their high-stakes context. Fraud and deliberate misconduct stay actionable. Regulators can set clear safety standards in advance instead of leaving courts to reconstruct them afterward.
[C1.10] Accountability [clipped]

## Turn 3: PRO Rebuttal 1

- model: qwen3.8-max
- raw_words: 312
- clipped_words: 312
- claim_ids: [P2.1], [P2.2], [P2.3], [P2.4], [P2.5], [P2.6], [P2.7]
- cited_claim_ids: [C1.2], [C1.5], [C1.7]
- missing_claim_id_refs: (none)

[P2.1] CON frames this as “wrong party” [C1.2], but it assumes responsibility must go to whichever actor has exclusive control. Product liability has never worked that way. A carmaker and a negligent garage can both be liable when a defect and poor maintenance combine to cause a crash. The question is who was best placed to prevent the harm at lowest cost.
[P2.2] For base-model behavior, that is the provider: it controls training data, alignment, evaluations, refusal logic, licensing, and release gates.
[P2.3] CON says deployers choose medicine or finance, but providers choose what the model will do there. If a model predictably produces confident insulin-dosing advice unless constrained, the provider can add medical refusals, uncertainty flags, or high-risk restrictions before release. A hospital’s sloppy deployment does not erase the provider’s failure to build a foreseeable safety boundary. Liability can be apportioned; it need not be exclusive.
[P2.4] The “wrong instrument” objection [C1.5] overstates uncertainty. Courts routinely decide foreseeability and reasonable care for complex products. The proposition does not ask juries to invent AI engineering from scratch; it asks whether providers used safeguards already visible in their own toolkits: red-teaming, capability limits, abuse monitoring, clear warnings. If those precautions were cheap and known, skipping them is not innovation—it is externalizing risk.
[P2.5] Nor does liability require defensive blanket refusals. A safe system can distinguish “explain generally how vaccines work” from “give me a personalized drug dosage.” Product law demands reasonable design, not zero risk.
[P2.6] Finally, CON’s open-source worry [C1.7] is a reason to calibrate duties, not abolish them. Reasonableness can account for size and context. But if any actor releases powerful weights with known dangerous affordances and no restrictions, the injured public should not be the default insurer. Regulation can complement, but it often arrives late and cannot alone compensate victims or price risk into products.
[P2.7] Providers profit from foreseeable uses; they should bear foreseeable, preventable harms.

## Turn 4: CON Rebuttal 1

- model: claude-opus-5-5-high
- raw_words: 358
- clipped_words: 340
- claim_ids: [C2.1], [C2.2], [C2.3], [C2.4], [C2.5], [C2.6], [C2.7], [C2.8], [C2.9], [C2.10]
- cited_claim_ids: [P2.3], [P2.6], [P2.4]
- missing_claim_id_refs: (none)

[C2.1] PRO's rebuttal keeps the motion alive by quietly rewriting it. Liability is now "apportioned" [P2.3], duties are "calibrated" for size and context [P2.6], and the standard is whatever was "already visible in their own toolkits" [P2.4]. Each retreat sounds reasonable. Together they confirm my central point: nobody can say in advance what the rule requires.
[C2.2] A jury will say afterward.
[C2.3] Take the insulin example. PRO says the provider should have added medical refusals before release. But the same model inside an endocrinology clinic, with a physician reviewing every output, should help with dosing. That is the point of deploying it there.
[C2.4] The provider cannot know which context it is in; the hospital can. A dosing answer is a defect for an unsupervised teenager and a feature for a supervised clinician. When whether a "defect" exists depends on the deployment, PRO's garage analogy fails. A brake is defective in every driveway.
[C2.5] Responsibility belongs with whoever can see the driveway.
[C2.6] Next, "courts routinely decide reasonable care for complex products." Yes, against mature benchmarks: crash-test norms and decades of engineering consensus. PRO's substitute benchmark is the provider's own toolkit. Follow the incentive.
[C2.7] Every red-team report a lab publishes and every internal evaluation it runs becomes Exhibit A for what it "knew or should have known." The rational response is to test less, document less, and publish nothing. PRO's rule penalizes the transparency that safety research depends on.
[C2.8] On open weights, PRO now says "any actor" releasing powerful weights without restrictions is exposed, softened by calibration a court will define years later. A university lab cannot plan around that, so it will not release. The frontier giants can price that uncertainty in. Concentration is not a side effect of PRO's rule; it is the predictable result.
[C2.9] Finally, PRO says regulation "arrives late." Litigation arrives later still: after the injury, after years of discovery, and only for victims who can afford to sue.
[C2.10] This is the clash. Should AI safety standards be set before deployment, by people who see the use case? Or should they [clipped]

## Turn 5: PRO Pressure Questions

- model: qwen3.8-max
- raw_words: 55
- clipped_words: 55
- claim_ids: [P3.1], [P3.2]
- cited_claim_ids: [C2.5]
- missing_claim_id_refs: (none)

[P3.1] Q1: You say responsibility belongs with whoever can see the driveway [C2.5], but if providers foresee thousands of unsupervised medical queries, why isn’t a missing refusal or warning a defect?
[P3.2] Q2: If deployers bear responsibility instead, what remedy do victims have when the deployer is insolvent or anonymous, but the provider skipped cheap, known safeguards?

## Turn 6: CON Pressure Questions

- model: claude-opus-5-5-high
- raw_words: 77
- clipped_words: 77
- claim_ids: [C3.1], [C3.2]
- cited_claim_ids: [C2.3]
- missing_claim_id_refs: (none)

[C3.1] Q1: For the insulin case [C2.3], name the specific safeguard a court should require of the provider before release, one that stops the unsupervised teenager without disabling the supervised clinician. If you cannot draw that line in advance, how is "reasonable safeguards" anything other than a jury's hindsight?
[C3.2] Q2: If a lab publishes red-team findings about a risk, does that publication make later harm "foreseeable" and the lab liable? If so, why would any lab keep publishing?

## Turn 7: PRO Rebuttal 2

- model: qwen3.8-max
- raw_words: 303
- clipped_words: 303
- claim_ids: [P4.1], [P4.2], [P4.3], [P4.4], [P4.5], [P4.6]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P4.1] A1: A feasible safeguard is tiered medical gating. For individualized dosing requests, the default consumer model should refuse or respond with general information, uncertainty warnings, and escalation to a clinician. A supervised clinic can unlock dosing assistance only through a professional deployment with verified human review, audit logs, and clear limits. That stops the unsupervised teenager while preserving the clinician’s tool.
[P4.2] The line is not perfect, but product law regularly asks for feasible design choices—interlocks, warnings, distribution controls—not omniscience. If providers cannot draw the line, that is a reason to require reasonable attempts, not to let them ship without one.
[P4.3] A2: Publishing red-team findings does not by itself create liability. It is evidence of what was known, but liability still requires that the harm was foreseeable and that reasonable, practicable safeguards were omitted. A lab that discloses a risk and then implements refusals, warnings, monitoring, or access limits is doing exactly the law should encourage. A lab that discloses and then does nothing is not being punished for transparency; it is being punished for choosing cheap risk over cheap prevention.
[P4.4] These answers decide the debate. CON keeps saying standards are hard, so providers should not answer for preventable injuries. But the whole point of product-liability-style responsibility is that complex products create asymmetric knowledge. Providers control training, alignment, evaluations, and release gates; they can build tiered safeguards before millions of users encounter them.
[P4.5] Deployer liability alone fails when the deployer is insolvent, anonymous, or merely a thin wrapper around the model’s dangerous default behavior. Apportionment solves this: courts can assign shares to provider and deployer according to fault, without letting either escape.
[P4.6] The real choice is whether avoidable harms are priced by the firm that profits from the model or dumped on victims. CON’s uncertainty argument protects the former; PRO’s rule protects the latter.

## Turn 8: CON Rebuttal 2

- model: claude-opus-5-5-high
- raw_words: 363
- clipped_words: 340
- claim_ids: [C4.1], [C4.2], [C4.3], [C4.4], [C4.5], [C4.6], [C4.7], [C4.8], [C4.9], [C4.10], [C4.11]
- cited_claim_ids: [P4.1], [P4.2], [P4.3]
- missing_claim_id_refs: (none)

[C4.1] A1: A missing refusal is not automatically a defect, because refusal has costs too. Block every unsupervised medical query and you also block the person asking what a dosing chart means at midnight. Whether a provider struck that balance reasonably has no benchmark yet, so a jury decides after an injury, when every gap looks obvious. When the provider runs its own consumer app, it is the deployer.
[C4.2] It can see that driveway, and existing negligence and consumer-protection law already reach it. No new product-liability regime is needed for that.
[C4.3] A2: Victims of an insolvent or anonymous deployer need a solvent payer. They do not need a new defendant. That can come from mandatory insurance or bonding for high-risk deployments. Providers can require it in their API terms, and regulators can make it a condition of entering medicine or finance.
[C4.4] That compensates victims without rewriting fault. Look at what PRO's version reaches. The anonymous actor misusing open weights is exactly the case where provider liability ends open release. We do not make toolmakers liable because a contractor vanished.
[C4.5] Searching for the deepest pocket is not a theory of responsibility.
[C4.6] Now look at PRO's own insulin answer [P4.1]. The safeguard works only because a clinic verifies itself as a professional deployment with human review. That means PRO's solution runs through the deployer's knowledge and choices. The provider supplies a switch; the deployer decides where it is flipped.
[C4.7] PRO has rebuilt my framework and called it provider liability.
[C4.8] PRO then concedes "the line is not perfect" [P4.2]. That is the whole case against the motion. An imperfect line is fine in a regulation written in advance. It is dangerous in a verdict written afterward.
[C4.9] On transparency, PRO says only the lab that "discloses and then does nothing" pays [P4.3]. Real labs never do nothing. They do something partial. Was a refusal that works most of the time enough?
[C4.10] A jury says, with the lab's own red-team report as Exhibit A.
[C4.11] So the clash is settled. PRO's answers protect victims only by leaning [clipped]

## Turn 9: PRO Closing

- model: qwen3.8-max
- raw_words: 188
- clipped_words: 188
- claim_ids: [P5.1], [P5.2], [P5.3], [P5.4]
- cited_claim_ids: (none)
- missing_claim_id_refs: (none)

[P5.1] The decisive reason PRO wins is that the provider controls the model’s default behavior, and default behavior is what makes harm foreseeable. CON concedes the provider can build a switch—medical refusal for unsupervised users, verified clinical mode for hospitals—then argues that because the deployer flips the switch, responsibility shifts.
[P5.2] But a product is not safe merely because a safer setting exists somewhere if the maker ships it with the dangerous default enabled. If a car’s brakes could work only after a dealer installs a missing part, we still blame the manufacturer for shipping without it.
[P5.3] CON’s fallback—make deployers or insurers pay—does not answer the core injury. It leaves victims of insolvent or anonymous deployers uncompensated and lets providers profit from predictable risk while treating preventable safeguards as optional. Product liability has always asked imperfect questions about reasonable design; that difficulty is why we use courts and apportionment, not why we abandon responsibility. The firm that designs, tests, and releases the model is the cheapest actor to prevent the harm, so it should bear the cost when reasonable safeguards were omitted.
[P5.4] That is the simple, durable rule PRO defends.

## Turn 10: CON Closing

- model: claude-opus-5-5-high
- raw_words: 224
- clipped_words: 220
- claim_ids: [C5.1], [C5.2], [C5.3], [C5.4], [C5.5], [C5.6], [C5.7]
- cited_claim_ids: [P4.2]
- missing_claim_id_refs: (none)

[C5.1] The debate turns on one question: when is "safe" defined, and by whom?
[C5.2] PRO's closing rests on the "dangerous default." But PRO never told you what the safe default is. Refuse the midnight question about what a dosing chart means, and you have failed a patient. Answer it, and a jury may later call that answer a defect.
[C5.3] PRO itself conceded "the line is not perfect" [P4.2]. That is exactly where the brake analogy breaks. Everyone knows what a working brake is before the car leaves the factory. Nobody yet knows what a reasonable refusal rate is for a model that does a thousand different jobs.
[C5.4] So under PRO's rule, the line gets drawn after the injury, by a jury, with the lab's own red-team report as Exhibit A. The results are predictable. Labs test less and publish less. Models refuse more useful help.
[C5.5] Only the largest firms can absorb the uncertainty, so open release becomes a gamble few can afford. A rule sold as safety turns safety research into a legal liability.
[C5.6] Victims do not need that trade. They need a solvent payer and a clear standard. That means insurance for high-risk deployments, duties on the deployer who sees the use case, and rules written before release.
[C5.7] PRO offers responsibility in hindsight. CON offers it in advance, and only [clipped]
